ArticleMycopathologia2013
In vitro antifungal activity of micafungin and caspofungin against dermatophytes isolated from China.
Article in Mycopathologia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 22 citations in OpenAlex.
- Comprehensive Review on Tinea Infection Therapies: Allopathic and Herbal Approaches for Dermatophytosis.Recent advances in anti-infective drug discovery · 2025Review
- Phenotypic and Genotypic Identification of Dermatophytes from Mexico and Central American Countries.Journal of fungi (Basel, Switzerland) · 2023Article
- The in vitro Activity of Echinocandins Against ClinicalInfection and drug resistance · 2023Article
- In vitro antifungal activity of heterocyclic organoboron compounds against Trichophyton mentagrophytes and Microsporum canis obtained from clinical isolates.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- Synergism between the Antidepressant Sertraline and Caspofungin as an Approach to Minimise the Virulence and Resistance in the DermatophyteJournal of fungi (Basel, Switzerland) · 2022Article
- Molecular Identification and Antifungal Susceptibility Patterns of Dermatophytes Isolated from Companion Animals with Clinical Symptoms of Dermatophytosis.Journal of veterinary research · 2021Article
- Dermatophyte Resistance to Antifungal Drugs: Mechanisms and Prospectus.Frontiers in microbiology · 2018Review
- Newer Topical Treatments in Skin and Nail Dermatophyte Infections.Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aims of this study are to investigate the in vitro activities of micafungin and caspofungin that are two new echinocandin antifungal drugs against clinically isolated dermatophytes in China and to define MEC (minimal effective concentration) as the reading endpoints of this study in accordance with (Clinical and laboratory Standards Institute) CLSI M38-A2 reference.
methodsMinimal effective concentrations (MECs) of micafungin and caspofungin for 82 dermatophyte strains were determined according to CLSI (formerly NCCLS) M38-A2 broth microdilution methods.
results(1) The MEC(90s) of micafungin for Trichophyton violaceum and Trichophyton tonsurans were 0.25 μg/mL, and for Microsporum canis and Trichophyton verrucosum were 0.06 μg/mL. The MEC(90s) for Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum gypseum and Epidermophyton floccosum were 0.03 μg/mL. (2) The MEC(90s) of caspofungin for T. rubrum, T. violaceum and T. tonsurans were 1 μg/mL, and for T. mentagrophytes, M. canis, M. gypseum, E. floccosum and T. verrucosum were 0.5 μg/mL. (3) Compared with caspofungin, micafungin demonstrated lower MEC value to dermatophytes (P < 0.05).
conclusionsMicafungin has stronger in vitro antifungal activity than caspofungin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.